Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 pilot study of LX1606 in mild to moderate acute ulcerative colitis
2011-003532-32Phase 2Completed
- Sponsor
- Lexicon Pharmaceuticals, Inc.
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing LX1606 with Placebo (2 arms). Primary endpoint: Safety and tolerability of LX1606 after 8 weeks. Started Nov 2011; status: completed.
02
Drugs
telotristat ethyl
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2011-003532-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003532-32.